These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 6838286)

  • 21. Antihypertensive and humoral effects of verapamil and nifedipine in essential hypertension.
    Muiesan G; Agabiti-Rosei E; Castellano M; Alicandri CL; Corea L; Fariello R; Beschi M; Romanelli G
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S325-9. PubMed ID: 6184562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
    Petrie JR; Glen SK; MacMahon M; Crome R; Meredith PA; Elliott HL; Reid JL
    J Hypertens; 1995 Dec; 13(12 Pt 2):1842-6. PubMed ID: 8903664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beta-adrenergic blocking agents in the treatment of pregnancy-induced hypertension.
    Paran E; Holzberg G; Mazor M; Zmora E; Insler V
    Int J Clin Pharmacol Ther; 1995 Feb; 33(2):119-23. PubMed ID: 7757311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pharmacological control of heart rate].
    Sirtori CR; Franceschini G
    Ann Ital Med Int; 1994 Oct; 9 Suppl():29S-35S. PubMed ID: 7857754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duration of hydralazine action in hypertension.
    O'Malley K; Segal JL; Israili ZH; Boles M; McNay JL; Dayton PG
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):581-6. PubMed ID: 1102235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of propranolol and of verapamil on heart rate and blood pressure in hyperthyroidism.
    Clozel JP; Danchin N; Genton P; Thomas JL; Cherrier F
    Clin Pharmacol Ther; 1984 Jul; 36(1):64-9. PubMed ID: 6734051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydralazine once daily in hypertension.
    Silas JH; Ramsay LE; Freestone S
    Br Med J (Clin Res Ed); 1982 May; 284(6329):1602-4. PubMed ID: 6805621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate.
    Ahmed JH; Godden J; Meredith PA; Elliott HL
    Br J Clin Pharmacol; 1993 Aug; 36(2):93-8. PubMed ID: 8398588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the effects of felodipine, verapamil and hydralazine on the survival rate of rats subjected to lethal effects of oxygen free radicals.
    Jacinto SM; Jandhyala BS
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Oct; 346(4):457-61. PubMed ID: 1436130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute haemodynamic effects of felodipine, verapamil and hydralazine in the anaesthetized dog.
    Björkman JA; Ek L; Gustafsson D; Ljung B; Nordlander M
    Pharmacol Toxicol; 1991 Apr; 68(4):310-5. PubMed ID: 1866391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can blood pressure reduction induced by slow calcium channel blockade (verapamil) be reversed by calcium infusion?
    Midtbø K; Hals O
    Pharmacol Toxicol; 1987 May; 60(5):330-2. PubMed ID: 3615342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-invasive haemodynamic study in hypertensive subjects after treatment with verapamil slow release.
    Vulpis V; Seccia TM; Ricci S; Lograno MD; Daniele E; Pirrelli A
    Pharmacol Res; 1994; 30(2):153-60. PubMed ID: 7816743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioassay of the vasodepressor and cardiostimulatory effects of hydralazine and pyridazine derivative (DL-150) in hypertensive patients.
    Pasotti C; Nicrosini F; Marchetti M; Manzini A; Nicolis FB
    Farmaco Prat; 1976 Sep; 31(9):453-62. PubMed ID: 1010019
    [No Abstract]   [Full Text] [Related]  

  • 35. The role of a slow channel inhibitor, verapamil, in the management of hypertension.
    Gould BA; Mann S; Kieso H; Subramanian VB; Raftery EB
    Acta Med Scand Suppl; 1984; 681():117-23. PubMed ID: 6587750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Verapamil pharmacodynamics and disposition in young and elderly hypertensive patients. Altered electrocardiographic and hypotensive responses.
    Abernethy DR; Schwartz JB; Todd EL; Luchi R; Snow E
    Ann Intern Med; 1986 Sep; 105(3):329-36. PubMed ID: 3740673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of hydralazine on arrhythmias in congestive cardiomyopathy.
    Heer KR; Davies J; MacArthur CG
    Int J Cardiol; 1981; 1(2):117-21. PubMed ID: 7338416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of oral dose size on hydralazine kinetics and vasodepressor response.
    Shepherd AM; Irvine NA; Ludden TM; Lin MS; McNay JL
    Clin Pharmacol Ther; 1984 Nov; 36(5):595-600. PubMed ID: 6488679
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative efficacy and safety of immediate-release and controlled-release hydralazine in black hypertensive patients.
    Adir J; Janda SM; Curry CL; Taylor RE; Poku CD; Rotenberg KS
    Clin Ther; 1987; 9(6):640-50. PubMed ID: 3326679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of once daily hydralazine in inadequately controlled hypertension.
    Danielson M; Kjellberg J; Ohman P; Wernersson B
    Acta Med Scand; 1983; 214(5):373-80. PubMed ID: 6362341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.